UNSPSC 51431501: Eprosartan

This classification denotes an angiotensin ii receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2KH13Z0S0Y. European Medicines Agency schedules Eprosartan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06586MIG. Eprosartan generally arises in the molecular formula C23H24N2O4S.

UNSPSC 51431501 Eprosartan (Commodity) covers pharmaceutical supply contracts in which state and local governments and cooperative purchasing organizations procure branded and generic medications, including eprosartan and other cardiovascular and emergency-response drugs, for use by fire rescue, public health agencies, and state employee health plans. The scope of work spans supply of individual medication units with firm pricing, freight on board delivery, expiration-date warranties, and replacement logistics. Issuing bodies include municipal fire departments, state health and human services agencies, and multi-state cooperative purchasing alliances. One recent opportunity shows Tampa Fire Rescue as a repeat end-user within the City of Tampa's Purchasing Department; the Texas HHS Commission and Minnesota's multistate cooperative alliance also actively solicit under this code.

The City of Tampa issued IFB 26P00188 for Advanced Life Support Medications on April 24, 2026, with a response deadline of April 8, 2026 and an estimated contract value of $40,000, seeking 370 units of Labetalol HCI and related emergency cardiac drugs with nine-month minimum expiration dates and ten-calendar-day delivery, with a Small Local Business Enterprise set-aside of five percent up to $10,000. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across Minnesota, Oregon, and participating state and local government facilities, with contract term beginning July 1, 2026 and evaluation weighted 75 percent on price competitiveness. Recent activity concentrates in Florida, Texas, and Minnesota, with the Texas HHS Commission issuing a Request for Information on March 27, 2026 to assess vendor capacity for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels.